Open AccessIncidence of Mucositis in Patients Treated With Temsirolimus‐Based Regimens and Correlation to Treatment Response
Author(s) -
Liu Xiaochun,
LoRusso Patricia,
Mita Monica,
PihaPaul Sarina,
Hong David S.,
Fu Siqing,
McQuinn Lacey,
Asatiani Ekaterine,
Doyle Lawrence A.,
Chen Helen X.,
Hess Kenneth R.,
Kurzrock Razelle,
Naing Aung
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2013-0231
Subject(s) - mucositis , medicine , temsirolimus , incidence (geometry) , quality of life (healthcare) , oncology , intensive care medicine , discovery and development of mtor inhibitors , radiation therapy , pi3k/akt/mtor pathway , apoptosis , biochemistry , chemistry , physics , nursing , optics
Mucositis may limit the therapeutic window for mammalian target of rapamycin inhibitor‐based combination therapy, necessitating treatment interruptions and/or dose reductions. Optimizing treatment or prophylactic interventions for mucositis will enable patients to continue effective treatment while maintaining good quality of life.